HIV-1 Tat and morphine interactions dynamically shift striatal monoamine levels and exploratory behaviors over time

J Neurochem. 2024 Mar;168(3):185-204. doi: 10.1111/jnc.16057. Epub 2024 Feb 3.

Abstract

Despite the advent of combination anti-retroviral therapy (cART), nearly half of people infected with HIV treated with cART still exhibit HIV-associated neurocognitive disorders (HAND). HAND can be worsened by co-morbid opioid use disorder. The basal ganglia are particularly vulnerable to HIV-1 and exhibit higher viral loads and more severe pathology, which can be exacerbated by co-exposure to opioids. Evidence suggests that dopaminergic neurotransmission is disrupted by HIV exposure, however, little is known about whether co-exposure to opioids may alter neurotransmitter levels in the striatum and if this in turn influences behavior. Therefore, we assayed motor, anxiety-like, novelty-seeking, exploratory, and social behaviors, and levels of monoamines and their metabolites following 2 weeks and 2 months of Tat and/or morphine exposure in transgenic mice. Morphine decreased dopamine levels, but significantly elevated norepinephrine, the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), and the serotonin metabolite 5-hydroxyindoleacetic acid, which typically correlated with increased locomotor behavior. The combination of Tat and morphine altered dopamine, DOPAC, and HVA concentrations differently depending on the neurotransmitter/metabolite and duration of exposure but did not affect the numbers of tyrosine hydroxylase-positive neurons in the mesencephalon. Tat exposure increased the latency to interact with novel conspecifics, but not other novel objects, suggesting the viral protein inhibits exploratory behavior initiation in a context-dependent manner. By contrast, and consistent with prior findings that opioid misuse can increase novelty-seeking behavior, morphine exposure increased the time spent exploring a novel environment. Finally, Tat and morphine interacted to affect locomotor activity in a time-dependent manner, while grip strength and rotarod performance were unaffected. Together, our results provide novel insight into the unique effects of HIV-1 Tat and morphine on monoamine neurochemistry that may underlie their divergent effects on motor and exploratory behavior.

Keywords: 5-hydroxyindoleacetic acid (5-HIAA); dopamine; neuro-acquired human immunodeficiency virus (neuroHIV); norepinephrine; opioid use disorder; serotonin; tyrosine hydroxylase.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • 3,4-Dihydroxyphenylacetic Acid / metabolism
  • Analgesics, Opioid / pharmacology
  • Animals
  • Dopamine / metabolism
  • Exploratory Behavior
  • HIV Infections*
  • HIV-1* / metabolism
  • Homovanillic Acid
  • Humans
  • Mice
  • Mice, Transgenic
  • Morphine / pharmacology
  • Neurotransmitter Agents
  • tat Gene Products, Human Immunodeficiency Virus / metabolism

Substances

  • Morphine
  • Dopamine
  • 3,4-Dihydroxyphenylacetic Acid
  • Analgesics, Opioid
  • Homovanillic Acid
  • Neurotransmitter Agents
  • tat Gene Products, Human Immunodeficiency Virus